Kombinierter retinaler arteriovenöser Verschluss unter Interferon-β-Therapie

Jenisch, Teresa; Dietrich-Ntoukas, Tina; Renner, Agnes B.; Helbig, Horst; Gamulescu, Maria-Andreea

doi:10.1007/s00347-011-2448-0

Cited by 8 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Churg-Strauss syndrome (Hamann [20]), Behçet’s disease (Richards [37]), interferon treatment (Jenisch et al [24]).…”

Section: Case Presentationmentioning

confidence: 99%

Comorbidities in combined retinal artery and vein occlusions

Schmidt

2013

Eur J Med Res

View full text Add to dashboard Cite

BackgroundSeveral general diseases cause blindness in patients with simultaneous combined retinal artery and vein occlusion.Methods/patientsWe examined 14 patients with acute unilateral visual loss due to combined retinal artery and venous occlusions. All 14 patients presented at the Polyclinic over a period of about 3 years. Fluorescein angiography was carried out in 12 patients to confirm the diagnosis. Ten patients underwent Doppler sonography and 11 echocardiography.ResultsConcerning systemic diseases, 11 of our 14 patients presented several cardiovascular risk factors, i.e., immunocytoma and arterial hypertension and hypercholesterolemia in one patient; another patient had chronic bronchitis, tachycardia and hypercholesterolemia. Six patients presented coagulation anomalies, and eight patients had arterial hypertension.Doppler sonography revealed normal carotid arteries in nine of ten patients. In 8 of 11 patients, echocardiography displayed no cardiac abnormalities.Ophthalmoscopy revealed no emboli in any of these patients.ConclusionUnilateral simultaneous combined incomplete retinal artery and venous occlusions should be considered as one entity. Eleven of our patients presented comorbidities reflecting several cardiovascular risk factors. Immunological diseases, malignancies and coagulopathies can cause this ocular disorder, resulting in blindness. No emboli were found in any of these patients. Patients suffering from acute visual loss must be examined for the presence of systemic diseases to enable therapy at an early stage.

show abstract

“…Churg-Strauss syndrome (Hamann [20]), Behçet’s disease (Richards [37]), interferon treatment (Jenisch et al [24]).…”

Section: Case Presentationmentioning

confidence: 99%

Comorbidities in combined retinal artery and vein occlusions

Schmidt

2013

Eur J Med Res

View full text Add to dashboard Cite

show abstract

“…Five studies (11 patients) were from the Americas [ 1 , 4 , 7 , 13 , 17 ], nine (13 patients) from Asia [ 5 , 8 , 10 , 11 , 12 , 14 , 16 , 18 , 19 ] and five (5 patients) from Europe [ 2 , 3 , 6 , 9 , 15 ].…”

Section: Resultsmentioning

confidence: 99%

“…Branch occlusion of the central retinal artery (BRAO) with simultaneous obstruction of the central retinal vein (CRVO) is a rarely described occurrence [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 ], usually presenting with sudden, painless central and/or altitudinal vision loss. This condition, characterized by retinal whitening in the territory of the affected retinal arterial branch together with typical CRVO features (i.e., dilated, tortuous retinal veins, diffuse retinal hemorrhages, cotton wool spots, macular and disc edema, generalized delay in arteriovenous transit on fluorescein angiography), differs clinically from CRVO associated with the simultaneous occlusion of either the central retinal artery or a cilioretinal artery [ 20 , 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combined Branch Retinal Artery and Central Retinal Vein Occlusion: A Systematic Review

Pinna,

Zinellu,

Serra

et al. 2023

Vision

View full text Add to dashboard Cite

We performed a systematic review and analyzed the current available data on branch retinal artery occlusion (BRAO) with simultaneous central retinal vein obstruction (CRVO), a rarely described occurrence. MEDLINE/PubMed and ISI Web of Sciences searches were performed according to MOOSE guidelines. Studies were considered eligible if they (1) described patients with simultaneous BRAO + CRVO and (2) had been published in peer-reviewed journals. We initially identified 239 records from databases. Ultimately, only 19 reports met the selection criteria. Twenty-nine patients (15 men, 14 women; mean age 43 ± 15 years) were analyzed. Seventeen (59%) patients presented vascular risk factors. Mean visual acuity at onset and final visual outcome were 20/83 and 20/45, respectively, an insignificant improvement. Vision improved in 48% of cases. A marked heterogeneity in treatment approach was found. Eight (28%) patients received no therapy, whereas for 21 (72%) a large variety of topical and/or systemic drugs was given. In the treated group, mean visual acuity at onset and final visual outcome were 20/90 and 20/44, respectively, a not statistically significant improvement. Results suggest that combined BRAO + CRVO occurs at a younger age than isolated BRAO or CRVO. At present, there is insufficient evidence to support any specific management to improve vision in simultaneous BRAO + CRVO.

show abstract

“…Meanwhile, there are several reports of combined vascular occlusion (artery and vein) during interferon therapy 75,76. Interestingly, no fundus abnormalities were seen in the fellow eye.…”

Section: Interferonsmentioning

confidence: 97%

Ocular side effects of biological agents in oncology: what should the clinician be aware of?

Häger

Seitz

2013

OTT

View full text Add to dashboard Cite

During the last 20 years, biologicals have become increasingly relevant in oncologic therapy. Depending on the medication used, there are different profiles of ocular side effects. Although these can be present in up to 70% of patients, they are generally underreported in the literature. Therefore, the pathophysiological details of their development are often poorly understood. Herein we attempt to identify groups of biologicals to which a specific side effect profile can be assigned. We also tried to capture all relevant side effects and therefore conducted several database investigation including Medline, Cochrane library, and the drugs section of the US Food and Drug Administration (FDA), using the following search strings: “name of biological agent (both generic and commercial names)” AND “eye” OR “ocular”. If we found a side effect that has been associated with a drug, we researched Medline using the following search string: “name of biological agent” (both generic and commercial names) AND “term for the specific side effect”. Due to the wealth of material we report only the drugs that are approved by the FDA.

show abstract

Kombinierter retinaler arteriovenöser Verschluss unter Interferon-β-Therapie

Cited by 8 publications

References 10 publications

Comorbidities in combined retinal artery and vein occlusions

Comorbidities in combined retinal artery and vein occlusions

Combined Branch Retinal Artery and Central Retinal Vein Occlusion: A Systematic Review

Ocular side effects of biological agents in oncology: what should the clinician be aware of?

Contact Info

Product

Resources

About